Monika Rudkowska

Dr. Monika Rudkowska


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Karolina A. Wojtunik-KuleszaKarolina A. Wojtunik-Kulesza
Karolina A. Wojtunik-Kulesza
MRMonika Rudkowska
Monika Rudkowska
AOAnna Orzeł-Sajdłowska
Anna Orzeł-Sajdłowska
In June 2021, the world was informed about a new drug for Alzheimer’s disease approved by the FDA. Aducanumab (BIIB037, ADU), being a monoclonal antibody IgG1, is the newest AD treatment. The activity of the drug is targeted towards amyloid β, which is considered one of the main causes of Alzheimer’s disease. Clinical trials have revealed time- and dose-dependent activity towards Aβ reduction, as well as cognition improvement. Biogen, the company responsible for conducting research and introducing the drug to the market, presents the drug as a solution to cognitive impairment, but its limitations, costs, and side effects are controversial. The framework of the paper focuses on the mechanism of aducanumab’s action along with the positive and negative sides of the therapy. The review presents the basis of the amyloid hypothesis that is the cornerstone of therapy, as well as the latest information about aducanumab, its mechanism of action, and the possibility of the use of the drug.

Verified
Journal Article
Open access
PDF file
Karolina A. Wojtunik-KuleszaKarolina A. Wojtunik-Kulesza
Karolina A. Wojtunik-Kulesza
MRMonika Rudkowska
Monika Rudkowska
Kamila Kasprzak-DrozdKamila Kasprzak-Drozd
Kamila Kasprzak-Drozd
Anna OniszczukAnna Oniszczuk
Anna Oniszczuk
KBKinga Katarzyna Borowicz
Kinga Katarzyna Borowicz
Alzheimer’s disease (AD) is the leading cause of dementia and cognitive function impairment. The multi-faced character of AD requires new drug solutions based on substances that incorporate a wide range of activities. Antioxidants, AChE/BChE inhibitors, BACE1, or anti-amyloid platelet aggregation substances are most desirable because they improve cognition with minimal side effects. Plant secondary metabolites, used in traditional medicine and pharmacy, are promising. Among these are the monoterpenes—low-molecular compounds with anti-inflammatory, antioxidant, enzyme inhibitory, analgesic, sedative, as well as other biological properties. The presented review focuses on the pathophysiology of AD and a selected group of anti-neurodegenerative monoterpenes and monoterpenoids for which possible mechanisms of action have been explained. The main body of the article focuses on monoterpenes that have shown improved memory and learning, anxiolytic and sleep-regulating effects as determined by in vitro and in silico tests—followed by validation in in vivo models.

13 September 2024 in Molecules
Verified
Journal Article
Open access
PDF file
Karolina A. Wojtunik-KuleszaKarolina A. Wojtunik-Kulesza
Karolina A. Wojtunik-Kulesza
MRMonika Rudkowska
Monika Rudkowska
Katarzyna KlimekKatarzyna Klimek
Katarzyna Klimek
JMJarosław Mołdoch
Jarosław Mołdoch
MAMonika Agacka-Mołdoch
Monika Agacka-Mołdoch
Anna OniszczukAnna Oniszczuk
Anna Oniszczuk
Carvone, a natural monoterpene, has been identified in various plants, giving them a characteristic scent. Enantiomers (R-(–) and S-(+)) reveal specific biological activities that are successfully used in traditional medicine for their antifungal, antibacterial, antiparasitic, and anti-influenza properties. The presented paper is based on S-(+)-carvone, characterized by a specific caraway scent, which revealed rich biological activities both in vitro and in vivo. Thus, the aim of the study was to evaluate the potential anti-neurodegenerative activity of S-(+)-carvone, including in vitro experiments (butyrylcholinesterase inhibitory, neuro- and hepatotoxicity as well as neuro- and hepatoprotective activity), in vivo (memory acquisition, locomotor activity), and ex vivo (determination of S-(+)-carvone’s level in tissues collected from mice). Results revealed the multidirectional character of S-(+)-carvone. It has been shown that S-(+)-carvone is capable of butyrylcholinesterase inhibition (40% for 0.025 mg applied onto the plate), and neuroprotection and hepatoprotection at selective concentrations against reactive oxygen species generation and lipid peroxidation along with non-hepatotoxicity character. Additionally, multiple-dose administration of the monoterpene at a dose of 100 mg/kg had a positive influence on memory acquisition. Gas chromatography–mass spectrometry analysis of the plasma and the brain showed that S-(+)-carvone can cross the blood–brain barrier and accumulate in the hippocampus (0.217 µg/mg of tissue), a crucial part of the brain associated with cognition and mental functions.

Verified
Journal Article
Open access
PDF file
MBMonika Banach
Monika Banach
MRMonika Rudkowska
Monika Rudkowska
ASAgata Sumara
Agata Sumara
KBKinga Katarzyna Borowicz
Kinga Katarzyna Borowicz
Accumulating experimental studies show that antiarrhythmic and antiepileptic drugs share some molecular mechanisms of action and can interact with each other. In this study, the influence of amiodarone (a class III antiarrhythmic drug) on the antiseizure action of four second-generation antiepileptic drugs was evaluated in the maximal electroshock model in mice. Amiodarone, although ineffective in the electroconvulsive threshold test, significantly potentiated the antielectroshock activity of oxcarbazepine and pregabalin. Amiodarone, given alone or in combination with oxcarbazepine, lamotrigine, or topiramate, significantly disturbed long-term memory in the passive-avoidance task in mice. Brain concentrations of antiepileptic drugs were not affected by amiodarone. However, the brain concentration of amiodarone was significantly elevated by oxcarbazepine, topiramate, and pregabalin. Additionally, oxcarbazepine and pregabalin elevated the brain concentration of desethylamiodarone, the main metabolite of amiodarone. In conclusion, potentially beneficial action of amiodarone in epilepsy patients seems to be limited by neurotoxic effects of amiodarone. Although results of this study should still be confirmed in chronic protocols of treatment, special precautions are recommended in clinical conditions. Coadministration of amiodarone, even at low therapeutic doses, with antiepileptic drugs should be carefully monitored to exclude undesired effects related to accumulation of the antiarrhythmic drug and its main metabolite, desethylamiodarone.

Verified
Journal Article
Open access
PDF file
Karolina A. Wojtunik-KuleszaKarolina A. Wojtunik-Kulesza
Karolina A. Wojtunik-Kulesza
MRMonika Rudkowska
Monika Rudkowska
Katarzyna KlimekKatarzyna Klimek
Katarzyna Klimek
MAMonika Agacka-Mołdoch
Monika Agacka-Mołdoch
JMJarosław Mołdoch
Jarosław Mołdoch
AMAgnieszka Michalak
Agnieszka Michalak
Citral, a common monoterpene found in numerous plants, is an interesting compound that has been shown to have various biological activities. Although it is widely distributed in nature and there are many studies presenting its biological activities, its anti-neurodegenerative activity, especially under in vivo conditions, is very poorly understood. Thus, this paper aimed to deepen knowledge about citral activity towards factors and symptoms of neurodegeneration. To accomplish this, several comprehensive tests were conducted, including the estimation of butyrylcholinesterase inhibition, the evaluation of hepatotoxicity and the detection of oxidative stress and lipid peroxidation in vitro, as well as an in vivo behavioral assessment using mice models. Additionally, ex vivo determination of level of the compound in the brain and blood of a tested animal was undertaken. The results obtained revealed that citral is able to inhibit butyrylcholinesterase activity and protect hepatic cells against oxidative stress and lipid peroxidation in vitro. Moreover, behavioral tests in vivo indicated that citral (50 mg/kg) improves memory processes associated with acquisition (passive avoidance test), both in acute and subchronic administration. Additionally, we found that the administration of citral at 25 mg/kg and 50 mg/kg did not significantly affect the locomotor activity. Beyond the aforementioned, gas chromatography-mass spectrometry analysis revealed the presence of the compound in the blood and brain after subchronic administration of citral. Taken together, the results obtained in vitro, in vivo and ex vivo clearly indicate that citral is a promising monoterpene that can potentially be used towards cognition improvement.

20 November 2025 in Food Chemistry
Verified
Journal Article
Closed access
ASAgnieszka Starek-Wójcicka
Agnieszka Starek-Wójcicka
Elzbieta Grza̧dkaElzbieta Grza̧dka
Elzbieta Grza̧dka
KGKatarzyna Gołębiowska
Katarzyna Gołębiowska
ASAgnieszka Sagan
Agnieszka Sagan
MKMarta Krajewska
Marta Krajewska
Joanna PawlatJoanna Pawlat
Joanna Pawlat